ReviewCurrent obesity reports2024
Hypothalamic-Ovarian axis and Adiposity Relationship in Polycystic Ovary Syndrome: Physiopathology and Therapeutic Options for the Management of Metabolic and Inflammatory Aspects.
Review in Current obesity reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07603505 (Effect of Nepeta Adenophyta Hedge Extract and Its Fractions on Polycystic Ovarian Syndrome), which is not on this map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Nepeta Adenophyta Hedge Extract and Its Fractions on Polycystic Ovarian Syndrome (PCOS)
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Serum anti-Müllerian hormone levels in women following bariatric surgery: insights from a systematic review and meta-analysis.BMC endocrine disorders · 2026Pooled it
- Traditional herbal medicine for obesity-related polycystic ovary syndrome: a meta-analysis and data mining study.Frontiers in pharmacology · 2025Pooled it
- Impact of mean arterial pressure on reproductive endocrine characteristics in infertile patients with polycystic ovary syndrome: a secondary analysis of a randomized clinical trial.Frontiers in endocrinology · 2025Trial
- Research progress on the role of IL‑37 in gynecological and obstetrics‑related diseases (Review).International journal of molecular medicine · 2026Review
- Article
- The Fibro-Inflammatory Ovary: Stromal Fibrosis, Extracellular Matrix Remodeling, and Mechanotransduction in Female Infertility.Current issues in molecular biology · 2026Review
- BMI-dependent methylation and clinical signatures in North Indian women with PCOS.The Indian journal of medical research · 2026Article
- Revisiting ESR in PCOS: an easily obtainable link to immune and metabolic dysregulation.Journal of ovarian research · 2026Article
- FAAH as a Molecular Regulator of Endocannabinoid Signaling: Mechanistic Insights into Reproductive, Metabolic, and Inflammatory Dysfunctions in Polycystic Ovary Syndrome.Molecules (Basel, Switzerland) · 2026Review
- Gut microbiota in PCOS: key microbial changes, potential mechanisms and clinical applications.Journal of translational medicine · 2026Review
- Atractylenolide III improves ovarian dysfunction and endometrial receptivity in a PCOS rat model by regulating Cybb-mediated oxidative stress.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Immunometabolic-uterine-ovarian interactions and flushing therapy in dairy cows: a narrative review.Veterinary world · 2026Review
- Article
- The Bushen Huatan formula inhibits TP53-Mediated ferroptosis and modulating lipid metabolism in polycystic ovary syndrome abnormalities rat model.Journal of ovarian research · 2026Article
- Effect of Exercise Therapy on Non-Obese Women with Polycystic Ovary Syndrome: A Protocol for a Randomized Controlled Trial.Complementary medicine research · 2026Article
- Elevated Visceral Adiposity Index is Associated with Reproductive Endocrine Characteristics, and Adverse Pregnancy Outcomes in Chinese Women with Polycystic Ovary Syndrome.International journal of women's health · 2026Article
- Comparison of live birth rates between calorie-restricted diet and metformin prior to ovulation induction therapy in women with polycystic ovary syndrome and overweight/obesity: a protocol for a multicenter, randomized comparative effectiveness trial.Frontiers in public health · 2026Article
- Association between oral microbial shifts and polycystic ovary syndrome: a systematic review.Journal of oral microbiology · 2026Review
- Effects of polycystic ovary syndrome on liver, heart, muscle, and pancreatic-related diseases.Frontiers in endocrinology · 2026Review
- Cardiovascular Dysfunction in Polycystic Ovary Syndrome: Mitochondrial and Inflammatory Mechanisms.BioMed research international · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe goal of the present review is to address the main adiposity-related alterations in Polycystic Ovary Syndrome (PCOS) focusing on hypothalamic-pituitary-ovarian (H-P-O) axis and to provide an overview of nutraceutical and pharmacological therapeutic strategies. RECENT
findingsFemale reproduction is a complex and delicate interplay between neuroendocrine signals involving the H-P-O axis. Elements that disrupt the balance of these interactions can lead to metabolic and reproductive disorders, such as PCOS. This disorder includes menstrual, metabolic, and biochemical abnormalities as well as hyperandrogenism, oligo-anovulatory menstrual cycles, insulin resistance, and hyperleptinemia which share an inflammatory state with other chronic diseases. Moreover, as in a self-feeding cycle, high androgen levels in PCOS lead to visceral fat deposition, resulting in insulin resistance and hyperinsulinemia, further stimulating ovarian and adrenal androgen production. In fact, regardless of age and BMI, women with PCOS have more adipose tissue and less lean mass than healthy women. Excessive adiposity, especially visceral adiposity, is capable of affecting female reproduction through direct mechanisms compromising the luteal phase, and indirect mechanisms as metabolic alterations able to affect the function of the H-P-O axis. The intricate crosstalk between adiposity, inflammatory status and H-P-O axis function contributes to the main adiposity-related alterations in PCOS, and alongside currently available hormonal treatments, nutraceutical and pharmacological therapeutic strategies can be exploited to treat these alterations, in order to enable a more comprehensive synergistic and tailored treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.